Essex Bio-Technology Limited

As of June 30, 2026, Essex Bio-Technology Limited carries a market capitalization of 1.51B, placing it among publicly traded companies globally. Its enterprise value stands at 1.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Essex Bio-Technology Limited's next confirmed earnings release is scheduled for March 11, 2027.

As of June 30, 2026, Essex Bio-Technology Limited has 566.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Essex Bio-Technology Limited maintains a current ratio of 2.15, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Essex Bio-Technology Limited's stock has declined approximately 54.50% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 3.07.

As of June 30, 2026, Essex Bio-Technology Limited holds 807.73M in cash and equivalents against 348.99M in total debt, resulting in a net debt position of -482.15M. Total book value stands at 2.55B, with working capital of 905.20M providing operational flexibility.